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Edited by Pascale CossartAbstract Intracellular parasitism by Chlamydiales is a complex
process involving transmission of metabolically inactive particles
that diﬀerentiate, replicate, and re-diﬀerentiate within the host
cell. A type three secretion system (T3SS) has been implicated
in this process. We have here identiﬁed small molecules of a
chemical class of acylated hydrazones of salicylaldehydes that
speciﬁcally blocks the T3SS of Chlamydia. These compounds
also aﬀect the developmental cycle showing that the T3SS has
a pivotal role in the pathogenesis of Chlamydia. Our results sug-
gest a previously unexplored avenue for development of novel
anti-chlamydial drugs.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Chlamydia spp. are obligate intracellular Gram-negative
bacteria that have a unique biphasic developmental cycle,
including two bacterial forms: a metabolic inert form termed
elementary bodies (EBs) that are able to enter host cells by
endocytosis and the metabolically active, replicating and
non-infectious reticulate bodies (RBs) [1].Abbreviations: C. pneumoniae, Chlamydia pneumoniae; C. trachomatis,
Chlamydia trachomatis; EB, elementary body; RB, reticulate body;
T3SS, type three secretion system; TARP, tyrosine phosphorylated
protein; Incs, inclusion membrane localized proteins; Y. pseudotuber-
culosis, Yersinia pseudotuberculosis; FCS, fetal calf serum; PBS,
phosphate buﬀered saline; MOI, multiplicity of infection; p.i., post
infection; Hsp90, Human 90 kD heat shock protein gene; ompA, outer
membrane protein A gene; wt, wild-type; nd, not detectable; DAPI,
4 0,6-diamidino-2-phenylindole; Ysc, Yersinia secretion
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doi:10.1016/j.febslet.2007.01.013Although the complete genomes of several Chlamydia spe-
cies are known [2–4], there are as yet no tools for genetic
manipulation of these organisms. The involvement of a type
three secretion system (T3SS) in the infectious cycle has been
suggested [5,6]. T3SSs are well-recognized virulence systems
in Gram-negative bacteria, e.g. human and animal pathogens
including Yersinia spp., Pseudomonas aeruginosa, Shigella
ﬂexneri, Salmonella typhimurium, enteropathogenic Esche-
richia coli and Chlamydia spp. [7]. The T3SS allows direct
transfer of eﬀector proteins into the host cell cytosol, creating
an environment supporting bacterial survival and proliferation
by targeting speciﬁc host proteins [7]. Components of the
T3SSs have been characterized and found to be conserved
among organisms possessing them. Unlike many bacterial
pathogens whose T3SS genes are grouped into large genomic
islands, the chlamydial components are scattered in several
clusters throughout the genome. Several studies have reported
a functional T3SS in Chlamydia spp. [6,8–10] and these reports
show similarities and diﬀerences between chlamydial T3SSs.
This can be exempliﬁed by the ﬁnding that Chlamydia pneumo-
niae seems to lack the phosphorylation site of the T3SS-asso-
ciated tyrosine phosphorylated protein, TARP, proposed to
be needed at the site of entry for C. trachomatis [11].
When C. trachomatis establishes its protective compartment
(inclusion), the bacterium secretes a set of unique proteins such
as the inclusion membrane localized proteins (Incs) via a T3SS-
dependent mechanism [6,12]. Importantly, some Incs have in-
deed been reported to be localized to the inside of the C. pneu-
moniae inclusion [8].
We have previously identiﬁed potential T3SS inhibitors
using a secretion linked reporter-gene assay to a screen of a
library of 9400 chemical compounds in viable Yersinia pseudo-
tuberculosis [13]. These hits were further investigated and a
class of acylated hydrazones of salicylaldehydes proved to be
speciﬁc T3SS inhibitors capable of preventing translocation
of Yersinia eﬀector proteins in a HeLa cell infection assay
[14]. Importantly, no obvious negative eﬀects could be ob-
served on the eukaryotic cells at concentrations inhibiting
T3SS, further underscoring the potential of these compounds
as in vivo T3SS virulence blocking agents. The homology be-
tween T3SSs of Yersinia and Chlamydia suggested to us that
inhibitors against the T3SS in Yersinia might also be capableblished by Elsevier B.V. All rights reserved.
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group have recently shown that T3SS inhibitors belonging to
the class of acylated hydrazones of salicylaldehydes cause a
dose- and growth phase-dependant inhibition of C. trachoma-
tis [15,16]. In the present study, we show that the T3SS inhib-
itor INP0010 speciﬁcally inhibits the C. pneumoniae
developmental cycle whereas INP0400 prevents intracellular
replication of both C. pneumoniae and C. trachomatis in
ex vivo infection models. Addition of the inhibitors led to a
10-fold decrease in transcription of the T3SS genes CPn0824
and CPn0702, respectively. In contrast transcription of incB
was in fact elevated twofold after addition of INP0010 while
incC transcription was unaﬀected by the compound. However,
addition of INP0010 did not allow the detection of the two
eﬀector proteins IncB and IncC. These results indicate that
the small molecule inhibitors obtained (acylated hydrazones
of salicylaldehydes) interfere with the T3SS of Chlamydia
and indicate an important role for T3SS in the chlamydial life
cycle. In addition our results indicate the possibility to develop
novel therapeutic agents for treatment of Chlamydia infections.
Moreover, these ﬁndings will also facilitate studies concerning
theT3SS-associated molecular mechanisms of virulence in
Chlamydia, since these inhibitors constitute a good substitute
for the lack of classical genetic methods and will allow us to
employ a chemical genetics approach.2. Materials and methods
2.1. Compounds
Compound INP0010 and its analogues INP0007, INP0406 and
INP0400 (shown in Fig. 1) were synthesized from commercially avail-
able hydrazides and salicylaldehydes, as described previously [13,14].
Stock solutions (10 mM) in DMSO were prepared and this solution
or a diluted DMSO solution was added to the assay mixtures. The ﬁnal
DMSO concentration was kept below 1%.
2.2. Mammalian cell lines
The human epithelial cell line HEp-2 (ATCC-CCL23, American
Type Culture Collection), HeLa cells and the mouse ﬁbroblastic cell
line McCoy were grown in RPMI 1640 supplemented with 10% fetal
calf serum (FCS, PromoCell), 20 mM HEPES, 8 lg/ml gentamicin
(Schering-Plough), 1 lg/ml amphotericin B (Gibco), and 2 mM L-glu-
tamine (Sigma). Cells were incubated at 37 C in the presence of 5%Fig. 1. Chemical structures of INP0007,CO2. J774 cells were used in the Yersinia ex vivo infection model as
described below. All cell lines and bacterial strains were negative
for Mycoplasma infection (Mycoplasma detection kit, Stratagene).2.3. Yersinia ex vivo infection model
J774A cells were seeded into a 96-well plate (7 · 104 cells/well) in
DMEM (Gibco) with 10% FCS and gentamicin (3 lg/ml), grown for
12 h at 37 C in 5% CO2. Wild-type (wt) Y. pseudotuberculosis YPIII
(pIB102) and the translocation-deﬁcient mutant, yopB (YPIII
(pIB604)) strains were grown in LB-broth supplemented with 25 lg/
ml kanamycin, diluted 1/10 in DMEM and incubated on a rotary sha-
ker at 26 C for 1 h followed by 2 h at 37 C. The J774A cells were
washed once with phosphate buﬀered saline (PBS) and 50 ll fresh
DMEM containing the diﬀerent compounds and 50 ll of T3SS induced
Y. pseudotuberculosis (OD600 = 0.002) was added, giving a ﬁnal MOI
of 10. After 16 h of infection CalceinAM (Molecular Probes; Invitro-
gen) in 20 ll PBS was added to a ﬁnal concentration of 1 lM and
the plate was incubated for 40 min at 37 C in 5% CO2. CalceinAM
is enzymatically transformed to a green ﬂuorescent molecule in healthy
cells (LIVE/DEAD Viability/Cytotoxicity Kit *for mammalian cells*,
Invitrogen;) [17], while cells that are killed during the infection stays
unstained (Fig. 2A). The ﬂuorescence was then read in the microtiter
plate reader (TECAN GENios); at 485/535 nm and the results were
conﬁrmed using ﬂuorescent microscopy. Each compound was tested
three times in this assay.2.4. Chlamydia strains and growth conditions
C. pneumoniae strain T45 [18] and C. trachomatis serovar L2 (ATCC
VR-902B) were propagated in HEp-2 cells as previously described [18].2.5. Chlamydia infection and immunoﬂuorescence
HEp-2 cells were seeded onto glass cover slips in a 24-well tissue
culture plate and incubated for 24 h prior to infection. Complete
medium containing INP0010, INP0406 or INP0400 was added to
the cells resulting in ﬁnal concentrations ranging from 2 to 30 lM.
C. pneumoniae or C. trachomatis was added at a multiplicity of infec-
tion (MOI) of 1–5 and the plate was centrifuged at 2500 rpm for 1 h
at 37 C. As a control, heat-inactivated C. pneumoniae (30 min in
60 C) was used. After 2 h incubation at 37 C in 5% CO2, the cells
were washed twice with ice cold PBS and the medium was changed
to complete medium with 0.5 lg/ml cycloheximide (Sigma) and
compounds were added as described above. Infected cells were
stained with Chlamydia culture conﬁrmation kit 48 h p.i. (Pathﬁnder;
Bio-Rad Laboratories) and visualized by immunoﬂuorescent confocal
microscopy (magniﬁcation 400–1000·). Digital images were processed
using the Adobe Photoshop software (Adobe Systems Inc.). The pro-
tocol used for immunoﬂuorescence staining with polyclonal anti-IncB
and anti-IncC was as described previously [8]. Minor modiﬁcationsINP0010, INP0400 and INP0406.
Fig. 2. INP0010 blocks yop translocation of Y. pseudotuberculosis. (A) Schematic illustration of the CalceinAM assay. Macrophages were infected
with bacteria and diﬀerent concentrations (0, 10, 20, 50 lM) of the compounds were added to the growth medium. Uninfected cells or cells infected
with a T3SS mutant were stained green due to transformation of CalceinAM to a green ﬂuorescent form by healthy cells. Cells infected and killed by
the wild-type bacteria were not stained. If a compound blocked the T3SS, the amount of green staining increased relative to the increased survival of
the eukaryotic cells. The diﬀerent concentrations of the compounds were also added to uninfected cells, if a compound was not toxic the cells were
stained green, while cells aﬀected by a toxic compound were not stained. Sixteen hours of incubation was required since the cells are killed by YopJ
that induces apoptosis between 8 and 16 h after onset of infection. (B) Survival of macrophages (J774) after treatment with INP0010 and (C)
INP0406. Macrophages were infected with the wild-type Y. pseudotuberculosis YPIII (pIB102) and the translocation deﬁcient mutant, yopB
(YPIII(pIB604)). Diﬀerent concentrations of INP0010 (0, 10, 20, 50 lM) were added to the growth medium. The ﬂuorescence intensity was measured
and the relative amount of living cells was calculated. As a control INP0010 was added to uninfected cells. Each bar represents the mean value of
three experiments and is calculated as percent of the control (uninfected cells without compound). Error bars indicate S.D.
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conjugated goat anti-rabbit IgG (Jackson, diluted 1:300 in BSA-
PBS) was used and further, 4 0,6-diamidino-2-phenylindole (DAPI)
was used for staining of host cell nuclei and intracellular bacteria
for 2 min.2.6. Cytotoxicity assays
HEp-2 cells were incubated in the presence of diﬀerent concentra-
tions (10, 20 or 50 lM) of INP0010, INP0400 or INP0406 and cell via-
bility was measured using CalceinAM, as described for the Yersinia
ex vivo model above.
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tigated by inverted phase contrast microscopy of HEp-2 and McCoy
cells cultured for 72 h at 10 lM INP0010. To exclude permanent cell
changes impairing Chlamydia infection, HEp-2 cells were cultured
for 24 h in the presence of 10 lM INP0010, thereafter washed three
times with PBS and subsequently infected with C. pneumoniae.
2.7. Real-time quantitative PCR
Quantitative real-time PCR (iCycler iQReal-Time PCR Detection
System; Bio-Rad) was used to monitor C. pneumoniae and HEp-2 cell
genome copy numbers. DNA was prepared using DNeasy tissue pro-
tocol for isolation of total DNA from cultured cells (Qiagen). Oligonu-
cleotide primers for the human 90 kD heat shock protein gene (Hsp90,
accession number J04988) were designed using Beacon Designer soft-
ware (v2.1; Premier Biosoft International, Palo Alto, CA, USA).The
forward primer (5 0-GGCACTTCGGGACAACTC-3 0) and the reverse
primer (5 0-AAGATAGCAGGGCGGTTTC-3 0) ampliﬁed a 170 bp
fragment detected by SYBR Green. A 79 bp fragment of the C. pneu-
moniae outer membrane protein A gene (ompA) was ampliﬁed as pre-
viously described [18]. Ampliﬁcation conditions were 3 min at 95 C
followed by 40 cycles of 30 s at 95 C and 30 s at 60 C according to
the manufacturer’s recommendations (IQ Supermix; Bio-Rad). All
samples were run in triplicate and experiments were repeated three
times or more. A correlation coeﬃcient of >0.98 was set as an accep-
tance criteria for each qPCR run.
For absolute quantiﬁcation of C. pneumoniae and host cell DNA,
plasmid constructs were used as external standards. The plasmid con-
struct coding for ompA has been described previously [18]. The 170 bp
hsp90 gene was ampliﬁed by PCR and cloned into a pGEM-T Easy
vector (Promega) and linearized with PstI. Tenfold dilutions of the
plasmid standard and genomic C. pneumoniae DNA dilutions between
34 copies and 3.4 · 106 copies and DNA extracted from of HEp-2
cells in dilutions between 20 copies and 2.0 · 105 copies were analyzed
by RT-PCR in the same run. Plasmid and genomic standards were
congruent. All obtained Ct-values from the samples were translated
to gene copy number by using the standard curves obtained from
the Ct-values of the genomic standards. A ratio of C. pneumoniae/host
cell was calculated.
2.8. RNA preparation and expression of T3SS genes
Infected HEp-2 cells were harvested at 30 h p.i. using TRIzol (Invit-
rogen) according to the manufacturer’s instructions for isolating RNA.
RNA preparation were treated with RNeasy minikit (Qiagen) using
the protocol for RNA cleanup with the addition of a DNase step.
In order to quantify expression levels of T3SS genes, the iScript one-
step RT-PCR kit with SYBR Green (Bio Rad) was used. Primers, as
described elsewhere, were speciﬁc for the 16 S RNA, incA, incB, incC
[8] yscC, yscS and groEL-1 [9]. The gene concentration was standard-
ized against the expression of bacterial 16S RNA transcripts and 20 ng
of mRNA template was used in all reactions. The program of the iCy-
cler was as follows: RT reaction of 10 min at 50 C followed by 5 min
at 95 C. The PCR was carried out during 45 cycles consisting of dena-
turation 10 s at 95 C and elongation 30 s at 60 C. A ﬁnal denatur-
ation step of 1 min at 95 C and a ﬁnal elongation step for 1 min at
55 C were conducted.
2.9. Statistical analysis
Analysis of variance with Bonferroni’s post hoc test for multiple
comparisons was used to analyze diﬀerences in the ratio of chlamydial
DNA copies to host cell DNA copies between INP0010 treated and
untreated infections. Concentrations of mRNA transcripts for
untreated or INP0010 treated cultures were compared by using
Mann–Whitney U-test for independent samples. A P value less than
0.05 considered signiﬁcant.3. Results
3.1. Inhibition of the Y. pseudotuberculosis T3SS in ex vivo
infection models
In a previous study, we showed that INP0007 (Fig. 1) and
several analogs are inhibitors of the T3SS of Y. pseudotubercu-
losis [14]. The aim of this study was to investigate if these com-pounds also have the ability to interfere with the T3SS of
Chlamydia. INP0007, however, exhibits limited water solubil-
ity and we therefore focused our interest towards the more sol-
uble analogue INP0010 (Fig. 1), that we anticipated should
facilitate our studies.
However, we ﬁrst had to characterize the eﬀect of INP0010
using our well-established Yersinia model.
To allow rapid testing of our T3SS inhibitors in a relevant
infection model, we have developed a 96-well plate high-con-
tent assay that measures both compound toxicity and blockage
of the T3SS of Yersinia by aﬀecting the level of phagocytosis in
a macrophage model. The status of the macrophages was ana-
lyzed using CalceinAM that is enzymatically transformed into a
green ﬂuorescent molecule in healthy living cells (see Fig. 2A).
This assay was used to study the potential of INP0010 to inhibit
T3SS of Y. pseudotuberculosis after infection of J774-macro-
phages. Wild-type bacteria caused cell death by translocation
of the eﬀector protein YopJ into the macrophage cytosol via
the T3SS [19,20] resulting in a reduced green ﬂuorescence signal
(Fig. 2A). Killed eukaryotic cells were unable to transform
CalceinAM resulting in a reduced green ﬂuorescence signal
(Fig. 2A). In contrast, the yopB translocation-defective aviru-
lent mutant had no eﬀect on macrophage viability (Fig. 2B).
Interestingly, for the wt strain 50 lM of INP0010 inhibited
T3S and the green ﬂuorescence signal was restored to the same
level as that of uninfected cells (Fig. 2B). Microscopic visual
inspection conﬁrmed this result since it was found that the mac-
rophages cleared wt bacteria from the medium after treatment
with INP0010 in contrast to non-treated cells (data not shown).
In addition, when INP0010 was added to uninfected J774 cells,
no eﬀect on cell survival was observed, i.e. the compound was
not toxic to macrophages (Fig. 2B). Thus, these results show
that the drug exhibits the desired functions resulting in a
T3SS-minus phenotype. Based on these data, INP0010 was
chosen for further studies on Chlamydia. We also included
the compound INP0406 (Fig. 1) as negative control. This com-
pound, which belongs to the same chemical class as INP0010, is
unable to inhibit the T3SS of Yersinia, and as expected
INP0406 showed no signiﬁcant inhibition of virulence and no
toxicity towards the macrophages (Fig. 2C).3.2. INP0010 inhibits C. pneumoniae but not C. trachomatis
infections in vitro
C. pneumoniae and C. trachomatis inclusions could be ob-
served in infected cells in the absence of INP0010 (Fig. 3a–c;
j–l). In contrast, no C. pneumoniae inclusions were observed
after treatment with INP0010 (10 lM) (Fig. 3d–f). Single
stained bacteria could occasionally be observed, but no inclu-
sions could be visualized. Identical results were observed when
McCoy and HeLa cells were used. When INP0010 (10 lM)
was added to Chlamydia infected cultures early in the develop-
mental cycle, before EBs undergo diﬀerentiation and develops
to RBs (8–12 h), no inclusions could be visualized 48 h post-
infection (Fig. 3d–f). We also found that pre-treatment of
the host-cells had no eﬀect on Chlamydia replication, i.e.
C. pneumoniae propagated normally when host-cells were ﬁrst
treated with a concentration of 10 lM of INP0010 for 4 h and
then the drug was washed away prior to infection. These re-
sults collectively suggest that INP0010 targets Chlamydia and
blocks the developmental cycle without interfering with the
eukaryotic host cell.
Fig. 3. Eﬀects of INP0010 on Chlamydia growth in HEp-2 cells. Left column represents the Evans blue stained HEp-2 cells (red), middle column
represents ﬂuorescein isothiocyanate stained chlamydial inclusions (green) and the right column is the merged overlay of the two staining methods.
All pictures were taken 48 h p.i. (a–c) C. pneumoniae infection (magniﬁcation, 630·). (d–f) C. pneumoniae infection treated with 10 lM of INP0010,
no bacterial inclusions were observed (magniﬁcation, 630·). (g–i) C. pneumoniae infection treated with 50 lM INP0406 (magniﬁcation, 630·). (j–l) C.
trachomatis infection (magniﬁcation, 400·). (m–o) C. trachomatis infection treated with 30 lM of INP0010 (magniﬁcation, 630·).
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matis, INP0010 at a ﬁnal concentration ranging from 10 to
30 lM no inhibitory eﬀect could be seen (Fig. 3m–o). In this
context, C. trachomatis can be regarded as a negative control
not responding to the compound, strongly arguing for the
hypothesis that INP0010 directly targets C. pneumoniae and
that the result is not an eﬀect of any adverse eﬀects of the drugon the eukaryotic host cell. Importantly, no inhibitory eﬀect
could be observed on either C. pneumoniae or C. trachomatis
infections treated with INP0406 at 10–50 lM, corroborating
the results obtained with Y. pseudotuberculosis (Fig. 3g–i),
and further supporting the idea that INP0010 targets the
T3SS of C. pneumoniae. Recently, we also showed that the
compound INP0400 inhibited intracellular replication of
592 L. Bailey et al. / FEBS Letters 581 (2007) 587–595C. trachomatis at 10 lM, analogous as seen here with C. pneu-
moniae infected cells treated with INP0010 at 10 lM (Fig. 3d–f
and [15]). Interestingly, intracellular replication of C. pneumo-
niae was similarly aﬀected by INP400 (data not shown). More-
over, when INP0400 was evaluated in the Y. pseudotuberculosis
ex vivo infection model it displayed the same proﬁle as
INP0010, i.e. it inhibited T3SS mediated virulence without
any detrimental eﬀect on the macrophages (data not shown).
In addition, none of the tested compounds were cytotoxic
for the eukaryotic host cells given at ﬁnal concentrations rang-
ing from 10, 20, or 50 lM as measured using CalceinAM
(Fig. 4). These results were also supported by microscopic
investigations showing that cell proliferation and morphology,
independent of cycloheximide, were unaltered in HEp-2 cells
grown in presence of 10 lM INP0010 for up to 72 h. However,
INP0010 blocked proliferation of C. pneumoniae both in pres-
ence and absence of cycloheximide (data not shown).3.3. INP0010 inhibits C. pneumoniae multiplication in a
dose-dependent manner
INP0010 was added at diﬀerent concentrations to test the
eﬃcacy of the compound. At 10 lM of INP0010, no inclusions
could be observed (Fig. 5A, B). To quantify the dose-depen-
dent eﬀect, the inclusions in a total of 1000 infected cells from
two independent experiments were counted by eye (Fig. 5B).
Quantiﬁcation of infecting chlamydiae was also carried out
with quantitative real-time PCR at 48 h p.i. in the presence
or absence of 2, 4, 6, 8, or 10 lM of INP0010 (Fig. 6). C. pneu-
moniae and HEp-2 cell genome equivalents were measured and
the ratio of chlamydiae per host cell was calculated. In the
absence of INP0010, there were in mean 103 (±2.3) chlamydiae
per host cell. Paralleling the results obtained with immunoﬂu-
orescence, the number of Chlamydia per host cell decreased
with increasing concentration of INP0010, and addition of
10 lM resulted in 11.7 (±3.9) chlamydiae per host cell.
Heat-inactivated C. pneumoniae was used as a control and
resulted in 5.8 (±0.8) chlamydiae per host cell, not signiﬁcantly
diﬀerent from treatment with 10 lM INP0010 (P < 0.001).
These results indicate that INP0010 blocks proliferation of
C. pneumoniae.Fig. 4. INP0010 and INP0406 exhibit non-toxic eﬀects on HEp-2 cells.
Diﬀerent concentrations of INP0010 and INP0406 (0, 10, 20, 50 lM)
were added to the growth medium of HEp-2 cells. The CalceinAM
ﬂuorescence intensity was measured and the relative amount of living
cells was calculated. Each bar represents the mean value of three
experiments and is calculated as percent of the control (uninfected cells
without compound). Error bars indicate S.D.3.4. Treatment with INP0010 inhibits chlamydial eﬀector
protein secretion and leads to decreased transcription of
T3SS speciﬁc genes
The above results suggested that INP0010 interferes with the
T3S machinery of Y. pseudotuberculosis, thereby inhibiting the
translocation of Yop eﬀectors into the host cell [14]. Therefore,
we asked the question if T3SS mediated secretion of two eﬀec-
tor proteins IncB and IncC of C. pneumoniae could be blocked
by the addition of INP0010 to infected host-cells. In absence of
INP0010 immunoﬂuorescence microscopy showed that IncB
was localized to the chlamydial inclusion (Fig. 7A). However,
in the presence of INP0010 (10 lM), no speciﬁc staining of
IncB could be observed (Fig. 7A), suggesting that IncB is
not secreted in the presence of INP0010. Similarly, we were un-
able to detect IncC in INP0010-treated cultures (data not
shown). Due to the fact that the number of bacteria was se-
verely reduced after drug treatment these results could be ques-
tioned. To further examine the role of INP0010 as a speciﬁc
inhibitor of the chlamydial T3S machinery, we analyzed also
the transcription of T3SS associated genes using quantitative
reverse-transcriptase PCR. Two genes were chosen as speciﬁc
markers for the T3SS of Chlamydia, CPn0824 and CPn0702,
respectively. These two genes show homology with the T3SS
genes yscS and yscC of Yersinia [9]. We also analyzed the level
of 16 S rRNA expression that was used as reference point since
this transcript is known to be stably expressed in Chlamydia
throughout the developmental cycle [8]. The groEL-1 gene, is
also known to be expressed throughout the complete develop-
mental cycle and since it has no known connection to the T3SS
this gene was selected as a marker for a gene not aﬀected by a
T3SS inhibitor. It was found that the relative amount of
mRNA transcribed from groEL-1 visa vie 16S rRNA did not
diﬀer signiﬁcantly between untreated and INP0010-treated cul-
tures (Fig. 7B). Interestingly, transcription of the Chlamydia
T3SS associated genes, CPn0824 and CPn0702, decreased sig-
niﬁcantly after treatment of INP0010 (10 lM) (P < 0.002).
However, when incB and incC transcription was determined
it was found that while incB transcription was elevated twofold
in the INP0010 treated cultures incC transcription was at the
same level as in untreated cultures. Taken together these re-
sults argue strongly for the idea that the compound INP0010
speciﬁcally targets the T3SS of C. pneumoniae resulting in
chemical attenuation of the pathogen. In addition, it also indi-
cate that that there is a regulatory coupling between the
expression of the T3SS and secretion in line with what has ear-
lier been described for Yersinia [21].4. Discussion
In a previous study, we identiﬁed INP0010 as a more soluble
and equally potent analog of the well-characterized Y. pseudo-
tuberculosis T3SS inhibitor INP0007 [14]. We show here that
INP0010 is also a potent inhibitor of C. pneumoniae infection
in cell culture and prevents formation of inclusions at 10 lM,
supporting our original hypothesis that T3SS-speciﬁc inhibi-
tors should be capable of blocking this evolutionarily con-
served virulence system in multiple species [13]. Importantly,
INP0406, a compound within the same chemical class as
INP0010, did not inhibit T3SS-mediated virulence in Y. pseu-
dotuberculosis and also failed to block replication of C. pneu-
moniae and C. trachomatis, arguing that the anti-chlamydial
Fig. 5. Dose-dependent inhibitory eﬀects of INP0010 on C. pneumoniae infection in HEp-2 cells. (A) Fluorescence staining of chlamydial inclusions
in HEp-2 cells after treatment of INP0010. C. pneumoniae growth inhibition assay using INP0010 at concentrations ranging from 2 lM to 10 lM
(magniﬁcation, 400·). To set a threshold, an inclusion was only counted when it was comparable in size and appearance to the inclusions observed in
untreated cells. (B) Inhibitory dose-dependent eﬀects quantiﬁed by immunoﬂuorescence. The dose-dependent eﬀect was demonstrated by counting
the total number of chlamydial inclusion in 1000 cells. No inclusions could be detected at 10 lM, marked as nd (not detectable). Each bar is presented
as an average from two independent experiments. Error bars indicate S.E.M.
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of a general toxic eﬀect on the eukaryotic cell. This was also
supported by the ﬁnding that INP0010 did not block replica-
tion of C. trachomatis although the compound had a profound
eﬀect on C. pneumoniae proliferation. We suggest that if
INP0010 exhibited a general toxic eﬀect on the eukaryotic cell,
the drug would not discriminate between the two diﬀerent
chlamydial species. Our ﬁnding that INP0010 blocked secre-
tion of the two eﬀector proteins IncB and IncC supports the
hypothesis that INP0010 targets the T3SS of Chlamydia per
se. However, it could be argued that we failed to detect the
presence of these two eﬀectors due to the fact that the drug
inhibited replication resulting in too low antigen levels. We
therefore employed the more sensitive RT-PCR method allow-
ing us to measure the relative amount of mRNA of T3SS asso-
ciated genes. We observed that transcription of the two T3SSlinked genes, CPn0824 and CPn0702, was decreased 10-fold
in the presence of INP0010 while the transcription of the
groEL-1 gene used as an internal control was unaﬀected. This
result corroborates the idea that the drug speciﬁcally targets
the T3SS but it also indicates that there is a regulatory link be-
tween the expression of the T3SS and secretion similarly to
what has been found to be the case for Yersinia [19]. We ob-
served also that transcription of incB showed a twofold in-
crease while incC transcription was unaﬀected. These results
indicate that expression of the IncB and IncC proteins is still
at wt levels or even higher after drug treatment. Thus, the fact
that we did not detect IncB and IncC after INP0010 addition is
more likely an eﬀect of the blockage of the T3SS than failure to
detect the proteins. These observations could not have been
made without the novel tools presented herein showing that
chemical genetics can substitute for the lack of suitable genetic
Fig. 7. INP0010 treatment inhibits IncB secretion and down-regulates
the T3SS genes CPn0824 and CPn0702. (A) Immunoﬂuorescence
double staining of the untreated infection revealed co-localization of
the bacteria (green) and IncB (red) within the peri-nuclear inclusion
(yellow, left column, and insert) 48 h p.i. (magniﬁcation, 630·). No
IncB-speciﬁc signal could be detected in INP0010-treated cultures at
(10 lM) (right column, arrows and insert). (B) Transcription of four
Fig. 6. Inhibition of C. pneumoniae infection with INP0010. Real-time
PCR was used to estimate the number of bacterial genomes. The
results conﬁrmed the ﬁnding described above (see Fig. 5). Non-treated
infected cells were used as positive control and cells with heat-
inactivated bacteria was used as negative control, denoted as Heat-
inact Cpn in the ﬁgure. Signiﬁcant diﬀerences were shown between
INP0010 (10 lM) untreated and treated Chlamydia infected cell
cultures (P < 0.05 is marked with an asterix).
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mydial T3SS at the molecular level. The ﬁnding that
INP0010 did not block replication of C. trachomatis at the
tested concentrations imply diﬀerences between the two chla-
mydial species and spurred us to attempt to identify an T3SS
inhibitor that also inhibits C. trachomatis at low concentra-
tions. Further screening resulted in INP0400 that blocked
T3SS mediated virulence in Y. pseudotuberculosis as well as
formation of inclusions both for C. pneumoniae and C. tracho-
matis [15]. These results indicated, in agreement with our ori-
ginal hypothesis, that the eﬀect of INP0010 and INP0400 on
the chlamydial replication is mediated by inhibition of the
T3SS of Chlamydia. Further work will focus on the identiﬁca-
tion of the molecular target(s) of this class of inhibitors. More-
over, a systematic search for additional compounds using our
high content CalceinAM assay, or chemical optimization of
existing inhibitors should result in T3SS inhibitors with im-
proved characteristics useful to study the diﬀerent T3SSs in
more detail.
In summary, the present study shows that the T3SS inhibi-
tors, of the chemical class of acylated hydrazones of salicylal-
dehydes, can inhibit chlamydial growth by interfering with the
T3SS without inﬂuencing the host cells. Hence, the discovery
of compounds through a chemical genetics approach demon-
strates the feasibility of a previously unexplored route to deve-
lop novel anti-chlamydial drugs to be used in basic and applied
research. Design, synthesis and evaluation of new libraries of
TTSS inhibitors against multiple species will allow us to
establish quantitative structure–activity relationships that will
guide us towards inhibitors either speciﬁc against a certain
organism or compounds capable of inhibiting T3SSs in a
broad manner.essential genes of the T3SS were analyzed by quantitative RT-PCR.
mRNA was prepared from six independent cultures treated and not
treated with 10 lM INP0010. Transcription of the T3SS associated
genes, CPn0824 (yscC), CPn0702 (yscS), incB and incC was analyzed
and compared to that of groEL-1 which was used as a negative control.
After INP0010 treatment at 10 lM 30 h p.i., transcription of CPn0824
and CPn0702 decreased signiﬁcantly (P < 0.002), while transcription of
incB showed a two-fold increase (P = 0.02) and incC transcription was
unaﬀected. The relative level of transcription of groEL-1 did not diﬀer
between untreated and INP0010-treated cultures. 16S rRNA was used
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